The biotechnology company uses a combination of chemical screening and structure-based design to discover and develop novel inhibitors for untapped protein targets. Elgia Therapeutics is focused on delivering first-in-class and best-in-class therapies for serious chronic diseases, including fibrosis, neuroinflammation, NASH, kidney disease, and IBD. The company's approach is based on its discovery of how metabolic stress drives inflammation and fibrosis, which has led to the identification of new targets for drug discovery. With its R&D expertise and pioneering biological insights, Elgia is well-positioned to offer effective treatment options for debilitating chronic diseases.